Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1100 Island Drive, Suite 101 REDWOOD CITY CA 94065 |
Tel: | N/A |
Website: | https://talisbio.com |
IR: | See website |
Key People | ||
Andrew A. Lukowiak President, Chief Scientific Officer | Robert Kelley Chief Executive Officer, Director | Rustem F. Ismagilov Co-Founder, Director | Rebecca Markovich Interim Chief Financial Officer |
Business Overview |
Talis Biomedical Corporation is engaged in transforming diagnostic testing by developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions at the point of care. The Company is engaged in developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system consists of compact instrument, single-use test cartridges and software that is designed to support a central cloud database, which work together and are designed to provide central laboratory levels of accuracy and be operated by an untrained user. It is also focused on developing Talis One assay kits for respiratory infections, and infections related to women's health and sexually transmitted infections (STIs). It is also developing influenza A and influenza B tests to be included as part of a respiratory panel with its COVID-19 assay (Respiratory Panel), as well as exploring adding a respiratory syncytial virus (RSV) test. |
Financial Overview |
For the fiscal year ended 31 December 2023, Talis Biomedical Corp revenues decreased 56% to $2.1M. Net loss decreased 45% to $62M. Revenues reflect Product revenue, net decrease of 89% to $412K. Lower net loss reflects Research and development decrease of 43% to $39.7M (expense), General and administrati decrease of 40% to $22M (expense), Other income, net increase from $2.1M to $4.8M (income). |
Employees: | 99 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $2.13M as of Dec 31, 2023 |
EBITDA (TTM): | -$63.25M as of Dec 31, 2023 |
Net annual income (TTM): | -$62.01M as of Dec 31, 2023 |
Free cash flow (TTM): | -$53.73M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 1,822,153 as of May 3, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |